Y. Im

发表

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

W. Eiermann, H. Rugo, L. Fehrenbacher, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer

S. Lee, J. Seo, H. Kwon, 2013, Investigational New Drugs.

Oxaliplatin and UFT Combination Chemotherapy in Patients With Metastatic Colorectal Cancer

Joon-Oh Park, W. Lee, Keunchil Park, 2002, American journal of clinical oncology.

A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer

K. Jung, J. Seo, H. Kim, 2017, Supportive Care in Cancer.

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.

T. Wilson, N. Harbeck, V. Diéras, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation

Joon-Oh Park, Keunchil Park, S. Park, 2004, Journal of Korean medical science.

Measuring response in solid tumors: comparison of RECIST and WHO response criteria.

Young Suk Park, Joon-Oh Park, Keunchil Park, 2003, Japanese journal of clinical oncology.

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.

J. Baselga, S. Swain, X. Pivot, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

J. Baselga, S. Swain, D. Miles, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.

H. Rugo, J. O’Shaughnessy, M. Gumus, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Sohee Park, S. Rha, J. Ro, 2012, BMC Cancer.

Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen

Joon-Oh Park, Keunchil Park, S. Park, 2004, American journal of clinical oncology.

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

M. Piccart, J. Jassem, S. Loibl, 2022, Annals of Oncology.

Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients withPIK3CA-mutant tumors

J. Baselga, T. Wilson, N. Harbeck, 2016 .

Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial

S. Swain, D. Miles, M. Beattie, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 2. Hepatocellular carcinoma with metastasis to the breast.

Joon-Oh Park, Keunchil Park, G. Kwon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.